Market Update: A Notable Downturn and Stock Analysis
The stock market faced a significant downturn this past Wednesday, causing all major indices to close in the red. Investor sentiment took a hit following Federal Reserve Chairman Jerome Powell’s cautious remarks regarding the U.S. economy. Powell indicated that current tariff policies could exacerbate inflation, steering the economy further from its recovery objectives.
The impact was most pronounced in the tech-heavy Nasdaq, which plummeted by 3.07%. The S&P 500 and the Dow Jones followed suit, declining by 2.24% and 1.73%, respectively. Such widespread market contractions highlight the current volatility investors are grappling with.
Analyzing Stock Performance: Who Took a Dive?
In our examination of the day’s trading, we focused on stocks boasting a market capitalization of $2 billion or more with at least $5 million in trading volume. The analysis allowed us to identify key movers within this turbulent market landscape.
One notable name, ImmunityBio, Inc. (NASDAQ: IBRX), saw its stock price drop for a second consecutive day. The company’s shares fell by 10.79%, closing at $2.48. This decline was largely attributed to profit-taking by investors amidst broader market losses.
ImmunityBio’s Recent Developments and Market Potential
Despite the recent downturn, ImmunityBio has made significant strides in the pharmaceutical realm. The company recently completed several submissions to the FDA, including a supplemental biologic license application for Anktiva—a groundbreaking immunotherapy targeting unresponsive non-muscle invasive bladder cancer. This development positions ImmunityBio as a key player in the oncology sector, with ambitious plans for global expansion.
Moreover, ImmunityBio submitted a marketing authorization request to the European Medicines Agency earlier this month. If approved, this could enable the sale of Anktiva across 27 European countries, including Norway, Iceland, and Liechtenstein—potentially unlocking substantial revenue streams.
The Investment Outlook
While ImmunityBio presents an intriguing investment opportunity, our analysis suggests that AI-focused stocks may offer more lucrative prospects in the near term. For instance, an AI stock outperformed the market by rising consistently since the beginning of 2025, even as many popular AI stocks saw declines of up to 25%.
For those exploring alternative investment routes, we recommend checking out our exclusive report on the cheapest AI stock, which is trading at less than five times its earnings and may provide a compelling investment case compared to IBRX.
Stay Informed
For insightful investment ideas, strategies, and stock analyses, stay connected with us. We curate the best investment insights, tailored specifically for the discerning investor.
Next Steps:
Don’t miss out on our upcoming articles featuring the 20 Best AI Stocks to Buy Now and 30 Best Stocks to Buy According to Billionaires. Subscribe to our newsletter to receive the latest insights, delivered straight to your inbox.
Disclosure: This article does not constitute investment advice. Always conduct thorough due diligence before making investment decisions.
Stay ahead in the world of finance with Extreme Investor Network—your trusted source for smart investment strategies.